tissue plasminogen activator

(redirected from Alteplase)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for tissue plasminogen activator

a thrombolytic agent (trade name Activase) that causes fibrinolysis at the site of a blood clot

References in periodicals archive ?
Again, no cases of intracranial hemorrhage or death were associated with alteplase therapy.
Nice Health and Technology Evaluation Centre director Professor Carole Longson said: "Today's draft guidance recommending the use of alteplase within the extended timeframe for which it is now licensed has the potential to have a significant impact on the treatment of thousands of patients.
Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism.
Clinicians also will not know how alteplase compares with other promising newer thrombolytic agents and, possibly, with other therapies.
In a third study that was reported in the Journal of the American Medical Association, for instance, some patients with basilar artery occlusion improved when alteplase was given intravenously more than 12 hours after symptom onset, Dr.
For the 70 percent of patients who received an intravenous dose of the clot-busting drug tPA, or alteplase, imaging studies conducted 30 minutes after tPA administration had to confirm that the vessel was still blocked.
Utilizing standard procedure, a total of 20 mg of alteplase was administered for over 90 minutes with residual occlusion of an early inferior segmental branch of the right M1 territory (Figure 2).
5) Alteplase was first approved in 1987 in major countries across the globe in the indication acute myocardial infarction, followed by subsequent approvals in the indications pulmonary embolism and acute ischaemic stroke (registered indications can vary across the globe).
Ten months on from the launch of the thrombolysis procedure, Walsall's Manor Hospital has decided to extend the hours and give patients 24/7 access to the alteplase drug.
But the value of adding reviparin or a similar agent remains in doubt when patients are treated with the fibrin-specific drugs typically used for thrombolysis in the United States, such as alteplase (tissue plasminogen activator), reteplase, and tenecteplase.
Stroke services lead Dr Elliot Epstein explained that thrombolysis entails administration of a 'clot busting' drug called alteplase.
Adding alteplase to heparin therapy improves the clinical course of hemodynamically stable patients with acute submassive pulmonary embolism, without raising the risk of major bleeding complications, said Dr.
Our service includes immediate CT scanning of patients and, if appropriate, the first dose of the alteplase bolus (clot dissolving agent) for Thrombolysis will be given in the scanning room once haemorrhagic stroke is excluded.